Quist

Biotech and Investment Veteran Dennis Purcell Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.

Retrieved on: 
Tuesday, May 5, 2020
JPMorgan Chase, Surname, Surnames, Hambrecht & Quist, Banks, Quist, Westport, Connecticut

Mr. Purcell is the Founder of Aisling Capital LLC and previously served as Senior Managing Partner.

Key Points: 
  • Mr. Purcell is the Founder of Aisling Capital LLC and previously served as Senior Managing Partner.
  • Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, H&Q).
  • He currently sits on the Boards of Real Endpoints, Summus Global, Inc., BioScience Managers Pty Ltd., and Ichnos Sciences.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

Bruckhaus Quist Appoints New Head for Its Feasible Financing Division

Retrieved on: 
Wednesday, February 5, 2020
Professional services, Finance, Surname, Surnames, Quist, Names

After a long and prosperous collaboration, Bruckhaus Quist is sadly announcing the departure of Mr. Shum Cheng-Lo, which headed the FFD since its inception.

Key Points: 
  • After a long and prosperous collaboration, Bruckhaus Quist is sadly announcing the departure of Mr. Shum Cheng-Lo, which headed the FFD since its inception.
  • Shum has over 35 years of experience in the feasible investments arena.
  • Bruckhaus Quist would like to thank him for imposing a high standard of work ethic behind all FFD activity, said Carrie Lai, Director of Bruckhaus Quists ESG Investment Department.
  • Bruckhaus Quist is a Hong Kong-based, global investment management firm.

Hambrecht Ducera Growth Ventures Leads Series B Round for Buoy Health, Joined by Humana, F-Prime and Optum Ventures

Retrieved on: 
Thursday, August 15, 2019
General Health, Health, Other Technology, Technology, Finance, Money, Economy, Investment banks, JPMorgan Chase, Bill Hambrecht, Hambrecht & Quist, OpenIPO, Optum, Quist, Fidelity Investments, Venture capital

By acting as a digital triage, Buoy has been shown to de-escalate the intent for nearly 40% of E.R.

Key Points: 
  • By acting as a digital triage, Buoy has been shown to de-escalate the intent for nearly 40% of E.R.
  • Bill Hambrecht, led the companys $15 million Series B round.
  • Hambrecht, who famously founded Hambrecht and Quist, is also credited for popularizing the OpenIPO model and organized the first J.P. Morgan Healthcare Conference.
  • The company also received additional funding from its existing investors F-Prime (Fidelity Investments venture capital firm) and Optum Ventures.